MX339537B - Sulodexide para uso en el tratamiento de patologias en donde estan involucradas las metalo proteinasas. - Google Patents

Sulodexide para uso en el tratamiento de patologias en donde estan involucradas las metalo proteinasas.

Info

Publication number
MX339537B
MX339537B MX2012012285A MX2012012285A MX339537B MX 339537 B MX339537 B MX 339537B MX 2012012285 A MX2012012285 A MX 2012012285A MX 2012012285 A MX2012012285 A MX 2012012285A MX 339537 B MX339537 B MX 339537B
Authority
MX
Mexico
Prior art keywords
sulodexide
pathologies
involved
treatment
metalloproteinases
Prior art date
Application number
MX2012012285A
Other languages
English (en)
Other versions
MX2012012285A (es
Inventor
Giuseppe Claudio Viscomi
Ferdinando Mannello
Cristiana Bruno
Original Assignee
Alfa Wassermann Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43063923&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX339537(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alfa Wassermann Spa filed Critical Alfa Wassermann Spa
Publication of MX2012012285A publication Critical patent/MX2012012285A/es
Publication of MX339537B publication Critical patent/MX339537B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/38—Stomach; Intestine; Goblet cells; Oral mucosa; Saliva
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cell Biology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Dispersion Chemistry (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención describe sulodexide o por lo menos uno de sus componentes para uso en la reducción de metaloproteinasas de matriz circulantes (MMPs), en particular MMP-9; el sulodexide y su composición son útiles para el tratamiento de patologías en donde las MMPs están involucradas, tal como la enfermedad cardiovascular, enfermedad cardiovascular causada por diabetes, venas varicosas, insuficiencia venosa crónica (CVI), úlceras gastrointestinales, enfermedad pulmonar, y patologías neoplásicas.
MX2012012285A 2010-04-23 2011-04-20 Sulodexide para uso en el tratamiento de patologias en donde estan involucradas las metalo proteinasas. MX339537B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITBO2010A000250A IT1401253B1 (it) 2010-04-23 2010-04-23 Uso del sulodexide per la riduzione delle metalloproteinasi di matrice.
PCT/IB2011/051726 WO2011132161A2 (en) 2010-04-23 2011-04-20 Sulodexide for use in the treatment of pathologies wherein metalloproteinases are involved

Publications (2)

Publication Number Publication Date
MX2012012285A MX2012012285A (es) 2012-11-23
MX339537B true MX339537B (es) 2016-05-30

Family

ID=43063923

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012012285A MX339537B (es) 2010-04-23 2011-04-20 Sulodexide para uso en el tratamiento de patologias en donde estan involucradas las metalo proteinasas.

Country Status (11)

Country Link
US (1) US8987231B2 (es)
EP (2) EP2609925B1 (es)
KR (2) KR20160060164A (es)
CN (1) CN102883728A (es)
ES (2) ES2694587T3 (es)
IT (1) IT1401253B1 (es)
MX (1) MX339537B (es)
PL (2) PL2609925T3 (es)
PT (2) PT2609925T (es)
RU (1) RU2557996C2 (es)
WO (1) WO2011132161A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20061692A1 (it) 2006-09-05 2008-03-06 Alfa Wassermann Spa Uso di polioli per ottenere forme polimorfe stabili di rifaximina
CA2926888C (en) * 2013-10-22 2020-03-24 Cell Receptor Sa Modulation of the physical interaction between platelets and the cell surface effecting cell proliferation
CN104398533B (zh) * 2014-11-26 2017-03-08 山东辰中生物制药有限公司 舒洛地特的生产方法
RU2667650C1 (ru) * 2017-12-15 2018-09-21 Федеральное государственное бюджетное образовательное учреждение высшего образования "Самарский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ лечения и профилактики острого тромбоза геморроидальных узлов

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2426586A1 (de) 1973-06-14 1975-01-09 Opocrin Srl Verfahren zur herstellung von glukuronil-glukosamin-glykan-sulfaten mit antilipaemischer wirkung
US4705798A (en) 1985-09-27 1987-11-10 University Of Iowa Research Foundation Phenylephrine prodrug useful as mydriatic agent
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
IT1242604B (it) * 1990-11-13 1994-05-16 Alfa Wassermann Spa Sali di glicosaminoglicani con esteri di aminoacidi, loro preparazione e formulazioni farmaceutiche che li contengono.
IT1245907B (it) * 1991-05-17 1994-10-25 Alfa Wassermann Spa Uso dei glicosaminoglicani nel trattamento della nefropatia diabetica e della neuropatia diabetica.
GB9215665D0 (en) 1992-07-23 1992-09-09 British Bio Technology Compounds
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
PL177245B1 (pl) * 1993-09-30 1999-10-29 Seikagaku Kogyo Co Ltd Środek przeciwzakrzepowy
IT1274351B (it) * 1994-10-06 1997-07-17 Alfa Wassermann Spa Uso di alcuni glicosaminoglicani nella dialisi peritoneale.
ES2233275T3 (es) 1995-12-08 2005-06-16 Agouron Pharmaceuticals, Inc. Intermediarios que sirven para la preparacion de inhibidores de metaloproteinasas.
IT1285546B1 (it) * 1996-01-16 1998-06-18 Alfa Wassermann Spa Uso del dermatano solfato a basso peso molecolare e delle specialita' medicinali che lo contengono nella terapia e nella prevenzione della
IT1299969B1 (it) * 1998-04-15 2000-04-04 Alfa Wassermann Spa Uso di sulodexide e delle specialita' medicinali che lo contengono nel trattamento della retinopatia diabetica.
DE69833822D1 (de) 1998-10-01 2006-05-11 Giovanni Gambaro Substanzen zur Vorbeugung von krankhafter TGF-beta Überexpression und Methoden derer Ermittlung
US20040009952A1 (en) 1998-10-19 2004-01-15 Giovanni Gambaro TGF-beta gene overexpression preventing substances for the treatment of disorders connected with pathological overexpression of TGF-beta
IL127896A0 (en) * 1998-12-31 1999-10-28 Gail Laster A novel treatment for preeclampsia and related diseases
US20090325876A1 (en) * 2004-09-29 2009-12-31 Saul Yedgar Use of lipid conjugates in the treatment of diseases associated with vasculature
US7259152B2 (en) 2000-06-07 2007-08-21 Alfa Wasserman, Inc. Methods and compositions using sulodexide for the treatment of diabetic nephropathy
PT1345612E (pt) 2000-12-16 2005-06-30 Aventis Pharma Gmbh Utilizacao de heparina de massa molecular reduzida para o tratamento de osteoartrose
FR2864087B1 (fr) 2003-12-19 2006-01-27 Aventis Pharma Sa Derives carboxy-reduits du dermatan sulfate, leur preparation, leur application comme medicament et les compositions pharmaceutiques les renfermant
KR100808131B1 (ko) * 2006-06-22 2008-02-29 부경대학교 산학협력단 인간 섬유육종 세포에서 메트릭스 메탈로프로테이나제-9의발현을 억제시키는 카복실화 키토올리고사카라이드 화합물및 이를 함유한 메트릭스 메탈로프로테이나제-9 억제제
CN101632686A (zh) * 2008-04-04 2010-01-27 马斯特里赫特大学 糖胺聚糖用于修复糖萼的用途
GB0919054D0 (en) 2009-10-30 2009-12-16 Isis Innovation Treatment of obesity

Also Published As

Publication number Publication date
CN102883728A (zh) 2013-01-16
IT1401253B1 (it) 2013-07-18
EP2609925A3 (en) 2013-09-04
PT2609925T (pt) 2018-11-22
WO2011132161A2 (en) 2011-10-27
KR20130072199A (ko) 2013-07-01
EP2560662B1 (en) 2017-06-07
KR20160060164A (ko) 2016-05-27
PT2560662T (pt) 2017-07-10
PL2609925T3 (pl) 2019-02-28
MX2012012285A (es) 2012-11-23
EP2609925B1 (en) 2018-10-17
US20130045946A1 (en) 2013-02-21
EP2560662A2 (en) 2013-02-27
WO2011132161A3 (en) 2012-03-08
PL2560662T3 (pl) 2017-09-29
RU2557996C2 (ru) 2015-07-27
ITBO20100250A1 (it) 2011-10-24
ES2628582T3 (es) 2017-08-03
RU2012142256A (ru) 2014-05-27
KR101739757B1 (ko) 2017-05-25
US8987231B2 (en) 2015-03-24
EP2609925A2 (en) 2013-07-03
ES2694587T3 (es) 2018-12-21

Similar Documents

Publication Publication Date Title
EA201500997A1 (ru) Терапевтические применения эмпаглифлозина
CL2011002989A1 (es) Compuestos heterociclicos inhibidores de la endopeptidasa neutra (nep); composicion farmaceutica; combinacion farmaceutica; uso del compuesto patra tratar un trastorno o enfermedad tal como hipertencion, insuficiencia cardiaca, insuficiencia renal, epilepsia, sindrome metabolico, entre otros.
PH12015502275B1 (en) Therapuetic uses of empagliflozin
EA201400119A1 (ru) Фармацевтическая композиция, способы лечения и их применение
MA32562B1 (fr) Composes organiques pour la cicatrisation de lesion
EA201501032A1 (ru) Фармацевтическая композиция, способы лечения и ее применения
EA201300583A1 (ru) Вазопротективное и кардиопротективное противодиабетическое лечение
EA201101117A1 (ru) Ингибиторы дпп-4 для лечения диабета у детей
MX356958B (es) Análogos de péptido-2 tipo glucagón (glp-2).
EA200970737A1 (ru) Оксабициклогептаны и оксабициклогептены, их получение и применение
EA201170521A1 (ru) Новые соединения
EA201170288A1 (ru) Оксабициклогептаны и оксабициклогептены, их получение и применение
DK201300152U1 (da) Antimikrobiel blanding og et dække til at understøtte sårheling, og som har en antimikrobiel aktivitet
WO2009026657A8 (en) Flavonoid ppar agonists
NZ721918A (en) Modified serpins for the treatment of bleeding disorders
EA201200046A1 (ru) Новые соединения, фармацевтическая композиция и связанные с ними способы
MX349254B (es) Compuestos para el tratamiento del sindrome metabolico.
UA108102C2 (uk) Біциклічні похідні і їх застосування як інгібіторів асс
CY1112821T1 (el) Ενωσεις για την επιλεκτικη θεραπεια της εντερικης ανοσο-φλεγμονωδους συνιστωσας της κοιλιοκακης
TR201907858T4 (tr) Müsinin rol oynadığı hastalıkların tedavisi.
GB201316955D0 (en) Composition comprising a diindolymethane and a retinoid to treat a skin condition
EA201401331A1 (ru) Дисковая тормозная система
MX339537B (es) Sulodexide para uso en el tratamiento de patologias en donde estan involucradas las metalo proteinasas.
EA201792669A1 (ru) Igfbp3 и его применение
EA201290954A1 (ru) Композиция для топического применения

Legal Events

Date Code Title Description
FG Grant or registration